Indication
Anticipated MA: For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Medicine details
- Medicine name:
- donidalorsen (Dawnzera)
- SMC ID:
- SMC2948
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC